Fast Five Quiz: Metastatic Hormone-Sensitive Prostate Cancer Treatment

Bradley Schwartz, DO; Daniel S. Schwartz, MD

June 27, 2022

Enzalutamide added to ADT appears to be beneficial for patients with both low-volume and high-volume mHSPC. Similarly, available evidence suggests that apalutamide plus ADT is also beneficial in patients with mHSPC regardless of disease volume.

While some clinicians may reserve docetaxel plus ADT for patients with high-volume disease, data conflict on its efficacy in patients with low-volume disease.

Learn more about treatment options for metastatic prostate cancer.

Editor's Recommendations

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Bradley Schwartz, Daniel S. Schwartz. Fast Five Quiz: Metastatic Hormone-Sensitive Prostate Cancer Treatment - Medscape - Jun 27, 2022.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.